Sole ProprietorEpiVac ConsultingAnchorage, Alaska, United States
Disclosure information not submitted.
224 - Immunosuppression and RSV Prefusion F Protein Vaccine Effectiveness in Older Adults: A Prespecified Subanalysis from the DAN-RSV Trial
Monday, October 20, 20253:15 PM - 3:27 PM US ET
228 - Real-world Abrysvo Vaccine Effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related Lower Respiratory Tract Disease (LRTD) Hospitalizations and Emergency Department Admissions over Two RSV Seasons—Kaiser Permanente of Southern California (KPSC), October 2023–April 2025
Monday, October 20, 20254:03 PM - 4:15 PM US ET
